Revenue Recognition (Tables)

6 Months Ended

Jun. 30, 2022

Revenue Recognition [Abstract]

Schedule of disaggregation of revenue

As of June 30, 2022, the Company had license and collaboration agreements with Vifor, Maruishi and CKDP. The following table provides amounts included in the Company’s Condensed Statements of Comprehensive Loss as revenue for the three and six months ended June 30, 2022 and 2021:

	Three Months Ended				Six Months Ended
	June 30, 2022		June 30, 2021		June 30, 2022		June 30, 2021
License and milestone fees
Vifor	$	15,000	$	—	$	15,000	$	—
Maruishi		—		—		—		1,192
Total license and milestone fees	$	15,000	$	—	$	15,000	$	1,192
Collaborative revenue
Vifor (KORSUVA injection profit sharing)	$	8,003	$	—	$	8,003	$	—
Maruishi		—		—		—		706
Total Collaborative revenue	$	8,003	$	—	$	8,003	$	706
Commercial supply revenue
Vifor (KORSUVA injection)	$	—	$	—	$	4,790	$	—
Total commercial supply revenue	$	—	$	—	$	4,790	$	—
Clinical compound revenue
Maruishi		—		—		—		37
Total clinical compound revenue	$	—	$	—	$	—	$	37